SECFilings.com reported the publication of an article showcasing Axim Biotechnologies Inc (OTCMKTS:AXIM) clinical progress and portfolio in light of Zynerba’s Phase II Cannabidiol gel patch failure. The clinical trial of 188 subjects with refractory epilepsy showed that those administered a low dose of ZYN002 recorded an 18.4% median drop in seizures versus a 14% drop […]

by

HB130 would let researchers who conduct institutional review board-approved studies possess and administer cannabinoid products to study participants, as well as import cannabis and related products from other states for study use— as long as the materials comply with federal law and are obtained from the National Institute on Drug Abuse. In January, Utah lawmakers […]

by

Daniel Sciubba, MD, a spine neurosurgeon at Johns Hopkins Medicine, discusses a case of a patient with kyphosis who was in pain following two spine surgeries to address injuries from extreme sporting accidents. During a two-day surgery, Sciubba removed the old hardware and reconstructed the patient’s spine. One year after surgery, the patient is cycling, […]

by

Zynerba Pharmaceuticals announces that results from Phase 2 STOP trial support continued development of ZYN002 in osteoarthritis. Zynerba Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today reported top line results from its Phase 2 STOP (Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis) clinical […]

by

Zynerba Pharmaceuticals announces that results from Phase 2 STOP trial support continued development of ZYN002 in osteoarthritis. Zynerba Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today reported top line results from its Phase 2 STOP (Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis) clinical […]

by

Zynerba Pharmaceuticals announces that results from Phase 2 STOP trial support continued development of ZYN002 in osteoarthritis. Zynerba Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today reported top line results from its Phase 2 STOP (Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis) clinical […]

by

brainPhoto Credit: Berkeley Lab In what is being heralded as a breakthrough for cancer research, GW Pharmaceuticals announced on Tuesday positive results from a study using a combination of cannabidiol and tetrahydrocannabinol to treat an aggressive form of brain cancer. Glioblastoma multiforme, or GBM is a “particularly aggressive brain tumor, with a poor prognosis,” according to the British-based biopharmaceutical […]

by

REDONDO BEACH, CA–(Marketwired – Aug 15, 2017) – SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc.’s. (OTCQB: AXIM) clinical progress and broad portfolio in light of Zynerba’s recent Phase II cannabidiol (CBD) gel patch failure. The clinical […]

by

DEVON, Pa., Aug. 14, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today reported top line results from its Phase 2 STOP (Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 (cannabidiol [CBD] gel). […]

by

DEVON, Pa., Aug. 14, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today reported top line results from its Phase 2 STOP (Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 (cannabidiol [CBD] gel). […]

by

In what is being heralded as a breakthrough for cancer research, GW Pharmaceuticals announced on Tuesday positive results from a study using a combination of cannabidiol and tetrahydrocannabinol to treat an aggressive form of brain cancer. Glioblastoma multiforme, or GBM is a “particularly aggressive brain tumor, with a poor prognosis,” according to the British-based biopharmaceutical company focused on […]

by

A dried flower bud of the Cannabis plant. Credit: Public Domain Robert MacCoun, a professor of law and a senior fellow at the Freeman Spogli Institute for International Studies, relays the potential risks and benefits of legalizing marijuana. His research focuses on drug policy, and he has written extensively about the effects of marijuana from […]

by